{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:19:21Z","timestamp":1747149561438,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data on substituting one antihypertensive medication with the proper dose of another antihypertensive medication, in certain medical conditions, are scarce. Herein, we present the results of replacing angiotensin\u2010converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) with the calcium channel blocker (CCB) amlodipine, with or without the alpha\u2010 and beta\u2010blocker carvedilol, to control high blood pressure in patients with coronavirus disease 2019 (COVID\u201019). Iranian hypertensive patients with COVID\u201019 and a history of taking ACEI or ARB were randomized to \u201ccontinue\u201d and \u201cchange\u201d groups. The continue group comprised patients who continued using their previous antihypertensive medication regimen as normal, whereas patients in the change group had their antihypertensive drugs changed to the CCB amlodipine, with or without the alpha\u2010 and beta\u2010blocker carvedilol, based on their response to amlodipine. Patients\u2019 blood pressures were measured for 8\u00a0days following their recruitment. A total of 31 and 33 patients were randomly allocated to the ACEI\/ARB continue and ACEI\/ARB change groups, respectively. No significant deviations were seen in patients\u2019 systolic blood pressure by substituting an ACEI\/ARB agent with the CCB amlodipine, with or without the alpha\u2010 and beta\u2010blocker carvedilol. Moreover, the change group had a more balanced systolic blood pressure (ie, 110\u2013130\u00a0mmHg) compared with the continue group (ie, 111.5\u2013140.0\u00a0mmHg) throughout their hospitalization period. During their hospitalization, the blood pressure of the change group was well controlled with the proposed equivalent doses. Further investigations of the proposed equivalent doses in larger randomized clinical trials, populations other than Iranian COVID\u201019 patients, and extended duration are encouraged (clinical trial registration ID: IRCT20151113025025N3).<\/jats:p>","DOI":"10.1002\/jcph.2294","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T10:09:14Z","timestamp":1687342154000},"page":"1205-1209","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood Pressure Control Following Angiotensin\u2010Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple\u2010Blind, Randomized, Clinical Trial"],"prefix":"10.1002","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-5964","authenticated-orcid":false,"given":"Amin","family":"Sharifan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care Sina Hospital Tehran University of Medical Sciences Tehran Iran"},{"name":"Research Center for Rational Use of Drugs Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Bahreini","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Sina Hospital Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Cardiac Primary Prevention Research Center (CPPRC) Cardiovascular Diseases Research Institute Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Najmeddin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmacy and Research Center for Rational Use of Drugs Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"e_1_2_10_3_1","unstructured":"Guideline for the pharmacological treatment of hypertension in adults.Geneva:World Health Organization;2021. Licence: CC BY\u2010NC\u2010SA 3.0 IGO."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16667"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.4749"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32833eeb19"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpab111"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08793"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00420-2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16451-9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00044"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.769"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00284-z"},{"key":"e_1_2_10_14_1","unstructured":"KanagasundaramS AshleyC BhojaniS et\u00a0al.UK Renal Association Clinical Practice Guideline for Acute Kidney Injury (AKI). Published online2019."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05800519"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012674"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.80"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:31:01Z","timestamp":1697182261000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/jcph.2294"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2294","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2023,7,9]]},"assertion":[{"value":"2023-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}